ALSUntangled #82: N-acetylcysteine

View at publisher
Authors: Sandeep Yerraguntla, Bhavya Bakshi, Keshav Chandran, Juliette Foucher, Michael Benatar, Paul J Wicks, Richard Bedlack, David Shirilla, Yuyao Sun, Nicholas John Maragakis, Ethan Greenstein, Javier Mascías Cadavid
+23 more Anusha Rao, Olivia Allen, Kara A. Dyckman, Olivia Wang, Morgan T Beauchamp, Vincent Chang, Andrew D. Brown, Olimpia Carbunar, Sabrina Paganoni, T E Bertorini, Erik Pioro, Basil Elsharif, Nan Jiang, Gary L. Pattee, Gregory Carter, Sarah R. Breevoort, Elia Tito, G. I. Nathaniel, Carlayne E. Jackson, Natasha J. Olby, Christopher J. McDermott, Dylan Ratner, Xiaoyan Li
Cited by: 0
References: 24

Abstract

N-acetylcysteine is a thiol-containing compound and a precursor of glutathione, with mechanistic plausibility for ALS, including reducing oxidative stress, regulating neuroinflammation, and mitigating mitochondrial dysfunction. Preclinical studies have yielded conflicting results on whether N-acetylcysteine can delay the onset of motor impairment and prolong survival in ALS mouse models. Several case studies of oral or subcutaneous administration of N-acetylcysteine in patients with ALS did not demonstrate convincing benefits. Clinical trials to date have also failed to demonstrate efficacy in slowing ALS progression. While N-acetylcysteine shows theoretical promise, further research is needed to clarify its therapeutic role in ALS. At present, ALSUntangled does not support the use of N-acetylcysteine as a treatment to slow ALS progression.

Fields of Study & Subjects

Amyotrophic Lateral Sclerosis Research Alzheimer's disease research and treatments Muscle Physiology and Disorders

Publication details

Journal / source
Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
Volume
27
Issue
5-6
Pages
717–721
Publication date
4 March 2026
Language
EN